Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. CRISPR/Cas9 Genome-Wide Loss-of-Function Screening Identifies Druggable Cellular Factors Involved in Sunitinib Resistance in RCC
  2. AGS-16C3F vs Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
  3. Nivolumab + Ipilimumab for First-Line Treatment of Advanced RCC: Extended 4-Year Follow-Up of CheckMate 214
  4. First-Line Axitinib Therapy Is Less Effective in Metastatic RCC With Spindle Histology
  5. Real-World Evidence of Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
  6. Role of Circulating Tumor Cells in Patients With Metastatic Clear-Cell Renal Cell Carcinoma
  7. Molecular Subsets in RCC Determine Outcomes in Response to Checkpoint and Angiogenesis Blockade
  8. Trends in Initial Systemic Therapy for Elderly Patients With Metastatic Clear Cell RCC
  9. 2020 Top Stories in Renal Cell Carcinoma: Breakthroughs in 2020 for RCC: A New First-Line VEGF-TKI and IO Combination and Immunotherapy as New Standards in Non−Clear Cell RCC and Sarcomatoid RCC
  10. Approach to Selection of Front-Line Therapy in the Metastatic RCC Setting

Elsewhere

Recently Updated